Antibody Drug Conjugates

Combining the targeting capabilities of antibodies and the cell-killing ability of cytotoxic drugs, Antibody-Drug Conjugates (ADCs) are an important and powerful therapeutic modality. Due to their molecular complexity and potential toxicity accompanied by a rapidly evolving technological landscape, ADC research demands a significant shift from traditional large molecule discovery and development paradigms. What sets apart Syngene from most global CROs is a highly integrated ‘one-stop-shop’ approach to ADC research, underpinned by strong conceptual frameworks, experimental design and expertise in troubleshooting. Augmented by expertise in target selection, antibody discovery, bioanalysis and cGMP manufacturing, Syngene can drive successful outcomes for our ADC clients.


Our ADC services

  • Linker-payload optimization, synthesis and scale up
  • Antibody engineering and production
  • Conjugation optimization and scale up
  • ADC purification and analytical characterization
  • Efficacy evaluation (in vitro and in vivo)
  • Pharmacokinetics and tox evaluation

Our track record

  • Development of a novel self-immolative linker-payload system (patent filed by client) from concept through pre-clinical proof
  • Employing a first in category antibody format to drive a candidate through to IND filing
  • Improvement of solubility and efflux properties of a class of payloads though rational design
  • Total synthesis of various novel payload analogs in several major categories (Duocarmycins, Tubulysins and PBD dimers)